PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer

Mayo Clinic Proceedings

Volumn 76, Issue 6, 2001, Pages 576-581

  Roberts, Steven G ^a   Blute, Michael L ^a   Bergstralh, Erik J ^a   Slezak, J M ^a   Zincke, H ^a  

^a MAYO CLINIC   (United States)

Author keywords

LR = local recurrence; PSA = prostate specific antigen; PSADT = prostate specific antigen doubling time; RRP = radical retropubic prostatectomy; SP = systemic progression

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PATIENT COUNSELING; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; SCORING SYSTEM; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT FAILURE;

EID: 0035003725     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/76.6.576     Document Type: Article

References (18)

1. Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point?
2. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer
3. Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control
4. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy
5. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer
6. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results
7. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years
8. Natural history of progression after PSA elevation following radical prostatectomy
9. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen
10. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: Correlation with histologic characteristics of the primary cancer
11. Radical prostatectomy for stage A adenocarcinoma of the prostate: Staging errors and their implications for treatment recommendations and disease outcome
12. Histologic grading and clinical staging of prostatic carcinoma
13. The value of serum prostate specific antigen determinations before and after radical prostatectomy
14. Prostate bed massage as a means to determine the source of a rising prostate specific antigen after radical prostatectomy
15. Influence of digital rectal massage on urinary prostate-specific antigen: Interest for the detection of local recurrence after radical prostatectomy
16. An analysis of urinary prostate specific antigen before and after radical prostatectomy: Evidence for secretion of prostate specific antigen by the periurethral glands
17. Percent of free prostate-specific antigen values in men with recurrent prostate cancer after radical prostatectomy